The discrimination was low (0.568, Table 2), and breast cancer-associated survival good, with lower than expected mortality, similarly to the BRCA1 carriers with ER-negative breast cancer (Table 3, Fig. 1). This evidence concerns the gene BRCA1 and breast carcinoma.